Myeloma progenitors in the blood of patients with aggressive or minimal disease: Engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCD mice

Blood

Volumn 95, Issue 3, 2000, Pages 1056-1065

  Pilarski, Linda M ^a,b   Hipperson, Gail ^a   Seeberger, Karen ^a   Pruski, Eva ^a   Coupland, Robert W ^a   Belch, Andrew R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BONE LESION; BONE MARROW; CANCER GROWTH; CELL RENEWAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; MYELOMA CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCID MOUSE; STEM CELL; XENOTRANSPLANTATION;

EID: 0034142369     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.3.1056.003k26_1056_1065     Document Type: Article

References (47)

1. Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med. 1993;178:1023.
2. Billadeau D, Quam L, Thomas W, et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood. 1992;80:1818.
3. Billadeau D, Van Ness B, Kimlinger T, et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood. 1996;88:289.
4. Corradini P, Voena C, Omede P, et al. Detection of circulating tumor cells in multiple myeloma by a PCR based method. Leukemia. 1993;7:1879.
5. Bakkus MHC, Van Riet I, Van Camp B, Thielemann K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Hematol. 1994; 87:68.
6. Berenson J, Wong R, Kim K, Brown N, Lichtenstein A. Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood. 1987;70:1550.
7. Berenson JR, Lichtenstein AK. Clonal rearrangement of immunoglobulin genes in the peripheral blood of multiple myeloma patients. Br J Hematol. 1989;73:425.
8. + peripheral blood cells expressing CD38, CD56 and monotypic immunoglobulin light chain. Blood. 1995;85:436.
9. Brown RD, Luo X-F, Gibson J, et al. Longitudinal analysis of circulating myeloma cells detected by allele specific mRNA in situ hybridization. Am J Hematol. 1998;58:273.
10. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ rearrangements. Blood. 1997;89:1824.
11. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. Blood. 1998; 92:2844.
12. Pilarski LM, Szczepek AJ, Belch AR. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood. 1997;90:3751.
13. Rasmussen T, Kastrup J, Knudsen LM, Johnson HE. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma. Br J Haematol. 1998;105:265.
14. Pilarski LM, Belch AR. Circulating monoclonal B cells expressing p-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood. 1994;83:724.
15. Lemoli RM, Fortuna A, Motta MH, et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood. 1996;87:1625.
16. + hematopoietic progenitor cells [abstract]. Blood. 1998;92:267b.
17. Gazitt Y, Tian E, Barlogie B, et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood. 1996;87:805.
18. Gazitt Y, Reading CC, Hoffman R, et al. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood. 1995;86:381.
19. Cassel A, Leibovitz N, Hornstein L, Quitt M, Aghai E. Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients. Exp Hematol. 1990;18:1171.
20. Corradini P, Voena C, Astolfi M, et al. High dose sequential chemotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood. 1995;85:1596.
21. Dreyfus F, Melle J, Quarre C, Pillier C. Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high dose chemotherapy. Br J Hematol. 1993;85:411.
22. Abonour R, Scott KM, Kunkel LA, et al. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone Marrow Transplant. 1998;22:957.
23. Henry JM, Sykes PJ, Brisco MJ, To LB, Juttner CA, Morley A. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol. 1996;92:614.
24. Mariette X, Fermand JP, Brouet JC. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high dose therapy. Bone Marrow Transplant. 1994;14: 47.
25. Billadeau D, Prosper F, Verfaule CM, Weisdorf D, Van Ness B. Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement. Leukemia. 1998;11:1565.
26. Attal M, Harosseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91.
27. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma - new biological insights and advances in therapy. Blood 1989; 73:865.
28. Greipp PR. Advances in the diagnosis and management of myeloma. Semin Hematol. 1992;29: 24.
29. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-SCID mice. J Immunol. 1995;154:180
30. Wang JC, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primative normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998;91:2416
31. Hogan CJ, Shpall EJ, McNully O, et al. Engraftment and development of human CD34+ enriched cells from umbilical cord blood in NOD/ LtSz-scid/scid mice. 1997;90:85.
32. Huang Y-W, Richardson JA, Vitetta ES. Anti-CD54 (ICAM-1) has anti-tumor activity in SCID mice with human myeloma cells. Cancer Res. 1995;55:610.
33. Huang Y-W, Richardson JA, Tong AW, Zhang B-Q, Stone MJ, Vitetta ES. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res. 1993;53:1392.
34. Bellamy WT, Odeleye A, Finley P, et al. An in vivo model of human multidrug resistant multiple myeloma in SCID mice. Am J Pathol. 1993;142:691.
35. Alsina M, Boyce B, Devlin RD, et al. Development of an in vivo model of human multiple myeloma bone disease. Blood. 1996;87:1495.
36. Feo-Zuppardi J, Taylor CW, Iwato K, et al. Long term engraftment of fresh human myeloma cells in SCID mice. Blood. 1992;80:2843.
37. Ashmann EMJ, van Tol MDJ, Oudemann-Gruber J, Lokhorst H. The SCID mouse as a model for multiple myeloma. Br J Haematol. 1995;89:319.
38. Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997; 90:754.
39. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-Hhu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92: 2908.
40. Arguello F, Baggs RB, Eskenazi AE, Duers RE, Frantz CN. Vascular anatomy and organ specific tumor growth as critical factors in the development of metastases and their distribution among organs. Int J Cancer. 1991;48:583
41. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 1988;48:6876.
42. Arguello F, Furlanetto RW, Baggs RB, et al. Incidence and distribution of experimental metastases in mutant mice with defective organ microenvironments (genotypes SISId and W/Wv). Cancer Res. 1992;52:2304.
43. Christianson SW, Greiner DL, Hesselton R, et al. Enhanced human CD4+ T cell engraftment in b2-deficient NOD SCID mice. J Immunol. 1997; 158:3578.
44. Yurasov S, Kollmann TR, Kim A, et al. Severe combined immunodeficiency mice engrafted with human T cells, B cells and myeloid cells after transplantation with human fetal bone marrow or liver cells and implanted with human fetal thymus: a model for studying human gene therapy. Blood. 1997;89:1800.
45. Deans JP, Wilkins JA, Caixia S, Pruski E, Pilarski LM. Prolonged expression of high molecular mass CD45RA isoform during the differentiation of human progenitor thymocytes to CD3+ cells in vitro. J Immunol. 1991;147:4060.
46. Pilarski LM, Mant MJ, Ruether BA. Review: analysis of immunodeficiency in multiple myeloma: observations and hypothesis. J Clin Lab Anal. 1987;1:214.
47. Bensinger WI, Demirer T, Buckner CD, et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant. 1996;18:527.